News

Teaser text
BioJapan has played an important role in facilitating interaction between Japanese and global companies/organizations and stimulating new business opportunities for almost two decades. Read more

Teaser text Recently we finished recruiting for a Phase I trial in patients with progressive multiple sclerosis. This randomized, double-blind, placebo-controlled study was designed to assess the safety and tolerability of a new biologic as well as the pharmacodynamics...
Read more

Teaser text As of today you can access a new paper published in The Lancet on 22 June 2018 on a combined multiple-ascending dose (MAD) and Phase IIa study in n=112 patients with controlled type 2 diabetes (HbA1c levels between 6.5–8.5%) via... Read more

Teaser text In January 2018 CRO’s Phase I unit moved from Campus Virchow-Klinikum (CVK) to Campus Mitte at Charité – Universitätsmedizin Berlin. Located at the very heart of Charité’s historic campus, the new facilities underwent extensive modernisation ... Read more

Teaser text As of today you can access our first case study that illustrates how - with our help - you can reach Proof of Concept faster. This particular case study deals with a  Phase IIa, single dose, double-blind, placebo-controlled, parallel study to assess the PD, PK ... Read more

Teaser text (Hannover, Germany) Bacteria worldwide keep developing new resistances to antibiotics. Alternative therapies are urgently needed to meet this challenge. To this end, the Fraunhofer Institute for Toxicology and Experimental ... Read more

Teaser text Charité Research Organisation will be present at the 2017 BioEurope in Berlin from November 6 to November 8. If you would like to meet, please contact us via enquiries@charite-research.org, +49-30-450 539 211 or the ... Read more